Standard Biotools (LAB) EBT Margin (2010 - 2026)

Standard Biotools (LAB) has 17 years of EBT Margin data on file, last reported at 69.11% in Q1 2026.

• On a quarterly basis, EBT Margin rose 4704.0% year-over-year to 69.11% in Q1 2026; TTM through Mar 2026 was 69.16%, a 3406.0% decrease from a year earlier, with the FY2025 full-year figure at 80.31%, down 5367.0% from the prior year.
• EBT Margin for Q1 2026 stood at 69.11%, down from 25.8% in the prior quarter.
• Over the last five years, EBT Margin for LAB reached as high as 567.21% in Q4 2022 and fell as low as 346.98% in Q2 2022.
• Historically, EBT Margin has averaged 51.95% across 5 years, with a median of 82.58% in 2023.
• On a YoY basis, EBT Margin climbed as much as 28647 bps in 2023 and fell as far as 51868 bps in 2023.
• Year by year, EBT Margin stood at 567.21% in 2022, then slumped by 91 bps to 48.53% in 2023, then soared by 226 bps to 158.4% in 2024, then tumbled by 84 bps to 25.8% in 2025, then sank by 368 bps to 69.11% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 69.11% in Q1 2026, 25.8% in Q4 2025, and 168.27% in Q3 2025.